(A) Cumulative rate difference of extended thromboprophylaxis with rivaroxaban per 10 000 patients utilizing various efficacy and safety end points. (B) Cumulative rate difference of extended thromboprophylaxis with rivaroxaban per 10 000 patients over time (45 days from randomization). ACM, all-cause mortality; CV, cardiovascular; MI, myocardial infarction; PE, pulmonary embolism. Reproduced with permission from Raskob et al.²⁶